Recruiting

Testing a new cancer-fighting drug alone and with an immune booster

Plain-English translation of NCT05941507 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This is a first-in-human study testing a new medication called , which is designed to find and attack cancer cells while sparing healthy tissue. Researchers will first test different doses of alone to find the safest and most effective level, then test it combined with another drug that helps the immune system fight cancer. The goal is to understand how well this treatment works for people with advanced solid tumors that haven't responded to standard care.

Many patients with advanced cancer run out of treatment options when standard therapies stop working. This medication targets a specific protein found on many cancer cells, offering a new potential path forward for people who need additional choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced cancer (solid tumors) that has not responded to standard treatments or for which no standard treatment exists
you are in good enough health to handle treatment, with normal blood counts and adequate organ function
you are willing to provide a tissue sample from your tumor (either an existing sample or a new biopsy) so researchers can study how the cancer responds
you have not had significant ongoing side effects from previous cancer treatments

You likely don't qualify if…

you have active or spreading cancer in your brain or spinal cord, unless it has been treated and stable for at least one month
you are currently taking cancer treatment or have taken it within the past 4 weeks
you are currently taking high-dose steroids (more than 10 mg of prednisone per day) for reasons other than managing brain tumors
you are experiencing moderate to severe side effects from previous cancer treatments that haven't resolved

What participation looks like

Participants will receive the medication as an intravenous infusion (through a vein) every three weeks. The study is divided into two phases: first, researchers test increasing doses to find the safest level, then they expand the study to confirm how well it works in specific cancer types. You'll have regular clinic visits for infusions, blood tests, and scans to monitor how your cancer responds, plus biopsies so doctors can understand how your tumor is changing.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Testing a new cancer-fighting drug alone and with an immune booster

What is this trial?

Do you qualify?

What participation looks like

Trial locations